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Study of the effect of formulation variables on the characteristics 
of combination tablets containing enalapril maleate and  
indapamide as active substances using experimental design
To evaluate the influence of different variables on tablet for-
mulations containing enalapril maleate and indapamide as 
active substances, two separate experimental designs were 
employed: one for evaluating powder properties and the 
other for tablet characteristics. Because of the low active 
pharmaceutical ingredient content, it was hypothesized 
that both powder and tablet properties could be deter-
mined only by the characteristics of excipients. In order to 
test this assumption, both experimental designs were done 
with placebo mixtures. The optimized formulation was 
then evaluated both with and without APIs. Results indi-
cated that filler and lubricant percentage, along with com-
pression force, were the most important variables during 
the formulation study. The optimized formulation showed 
similar characteristics in both cases for all responses, ex-
cept for angle of repose and friability where only minor 
differences were observed. The combination of the applied 
approaches (using placebo composition and fractional ex-
perimental design) proved to be efficient, cost effective and 
time saving.
Keywords: design of experiments, optimization, factorial 
design, placebo formulation 
Proper management of hypertension, one of the leading causes of cardiovascular dis-
ease, is of the utmost importance. It has been established that lowering of blood pressure 
can effectively reduce the risk of cardiovascular events and stroke, but finding the most 
appropriate therapy is often difficult (1). Combinational therapies employing an angioten-
sin-converting enzyme inhibitor (ACEi) and indapamide (IND) offer the advantage of us-
ing two highly effective agents, increasing both clinical efficiency and patient compliance 
(2–4). Low dose combinations of ACEis and diuretics have shown greater reduction in 
blood pressure and higher success rates in managing hypertension than either of the treat-
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dopril (2) and delapril (7), but the effectiveness of enalapril maleate (ENA) in combination 
with IND was also established (8). In some countries, the abovementioned combination is 
marketed as a commercial product (Enzix Duo), however only as two separate tablets (one 
containing enalapril maleate and the other indapamide) in the same packaging.
ENA is a relatively inactive pro-drug of the diacid long acting ACEi, enalaprilat. It is 
widely used in the treatment of essential hypertension, congestive heart failure and sev-
eral other cardiovascular diseases, such as left ventricular dysfunction (9). IND is a mem-
ber of the thiazide-like diuretic class, with uses which include hypertension, edema, in-
cluding that associated with heart failure (9).
In the early drug formulation phase, it is rather challenging to find the optimal com-
position of the dosage form and the most suitable manufacturing process variables. Tradi-
tional formulation development is based on changing one variable at a time, while keeping 
other variables constant until no further improvement is achieved. This is the so-called 
COST (changing one separate factor at a time) or OFAT (one factor at a time) method (10). 
Unfortunately, this method leads to a multitude of experiments, whilst gaining only little 
information about the process itself. It does not allow identification of the real optimum, 
because in most cases different starting points will lead to different optimums (10, 11).
In contrast to the COST method, the design of experiments (DoE) relies on a carefully 
selected representative set of experiments and statistical data processing in order to find 
optimal conditions. The main advantage of this approach is that it makes it possible to 
obtain maximum process information with a minimal number of experiments. The se-
lected factors are varied at different levels simultaneously, making it possible to detect not 
only the statistically significant main effects, but also possible interactions. As a result of 
DoE, process responses can be described as a mathematical function of several factors, 
making it possible to predict the outcome of unperformed experiments (12).
Before any experiments are made, some input conditions have to be specified, includ-
ing the experimental objective, the factors and their range and responses that will be 
monitored. After these conditions are selected, the experimental design is created and the 
specified experiments are carried out. The experimental data gained will then be investi-
gated using regression analysis and a model will be created based on the results, indicat-
ing which of the selected factors are important and how they influence the selected re-
sponses.
One of our main objectives was to systematically investigate the effect of selected 
process variables on the characteristics of both the powder blend and dosage form. In 
general, in the phase of early formulation development, a screening phase is desirable, 
employing a two-level full factorial design (11), assigning a high and a low level for each 
factor. However, when the number of factors is high, the number of experiments that 
should be performed increases (for 5 factors, in our case, the number of 25 = 32 experiments 
would be necessary). Fractional factorial designs are suitable for reducing the number of 
design runs, while still being able to identify the main effects. In our case, two separate 
designs were employed.
To characterize powder blends, the proportion of three different excipients and a sin-
gle process variable was studied by a fractional factorial design of resolution IV and a total 
of 11 runs (24–1 = 23 = 8 factorial points and three replicated center points). To investigate 
tablet properties, a fractional factorial design of resolution III was applied. Apart from the 
193
Z-I. Szabo et al.: Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate 
and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206.
 
four variables employed in the previous design, another process variable (compression 
force) was also studied. A total of 11 runs were employed (25–2 = 23 = 8 factorial points and 
three replicated center points).
Besides understanding the effect of variables upon powder and tablet characteristics, 
optimization of the formulation was also targeted. In order to improve both dosage form 
aesthetics and for stability reasons, a film coating was applied. Dissolution profiles were 




ENA (Esteve Quemica, Spain) and IND (Bioindustria, Italy) were kind gifts from the 
local pharmaceutical manufacturing companies. Lactose monohydrate (Flowlac 100) was 
purchased from Meggle Gmbh (Germany), microcrystalline cellulose (MCC) (Vivapur 102) 
was obtained from JRS Pharma (Germany), sodium croscarmellose (Disolcel) was from 
Mingtai Chemical Co. (Taiwan), while colloidal silicium dioxide (Aerosil 200) was pur-
chased from Degussa AG (Germany). Magnesium stearate (MgSt) was purchased from 
FACI SpA-Carasco GE (Italy) and Opadry II white 85F18422 from Colorcon Ltd. (United 
Kingdom).
Preparation of powder mixtures and tablets
Prior to mixing, the active substances (if present) and excipients (except MgSt) were 
passed through a 1 mm hand sieve. The powder blend was then mixed using an Erweka 
AR 402 mixer (Erweka, Germany) for 3 minutes at a rotation speed of 50 rpm. Thereafter, 
MgSt was added and further mixed at the same speed for the time specified in the experi-
mental design.
Evaluation of powder mixtures
Flow rate and angle of repose. – In order to evaluate flow behavior of the powder mixture, 
a total quantity of 100 g was collected from three different sampling points and analyzed 
using an automated powder testing system (Pharmatest PTG-S4, Pharmatest, Germany). 
The instrument is suitable for measuring the flow rate and angle of repose in accordance 
with pharmacopoeial stipulations. A conical stainless funnel, equipped with a pouring 
nozzle takes the sample to be tested and an analytical balance cell holds the powder col-
lecting dish. Flow rate is measured by recording the time needed for 100 g powder to flow 
through the pouring nozzle, while the angle of repose of the collected powder mound is 
also registered. Bulk and tapped density was determined using a Pharmatest PT-TD200 
(Pharmatest, Germany), according to method I in both cases, as described in the United 
States Pharmacopoeia (USP) (14).
Moisture content. – Moisture content of the mixtures was determined with a Halogen 
moisture analyzer Mettler-Toledo HR 83. The instrument determines the initial mass of the 
sample and afterwards the sample is heated and the mass loss is monitored until a con-
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stant mass is achieved. Once the drying has been completed, the moisture content of the 
sample is displayed.
Compression of tablets
Tablets containing ENA 10 mg and IND 2.5 mg were prepared employing the direct 
compression method. Taking into account the quantity of active substances, the tablet 
mass of 200 mg was selected. Powder blends were compressed into tablets using a Piccola 
D8 rotating tablet press (Riva, Argentina), at 20 rpm, on 8 mm diameter punches, to a 
round biconvex form.
Film coating procedure
Opadry II white 85F18422 was selected as film coating agent, a PVA-based fully formu-
lated dry blend for aqueous film coating of immediate release products. The Opadry sus-
pension with 15 % solid content was applied onto the surface of tablet cores at a spray rate 
of 5 g min–1 in a Uni-Glatt type fluid-bed system with Würster insert. Proper tablet surface 
covering was assured by the selected theoretical mass gain of 3 %. During the whole spray-
ing process, the product bed temperature was maintained between 42 and 44 °C.
Evaluation of tablets
Disintegration time. – Disintegration time was measured according to the method de-
scribed in European Pharmacopoeia 8 (Ph. Eur. 8) (13) using a fully automated six station 
disintegration tester (Pharmatest PTZ Auto 1EZ, Pharmatest, Germany). Temperature was 
maintained at 37 ± 0.5 °C and the time taken for each of the 6 tablets to disintegrate was 
recorded and the average disintegration time was calculated.
Friability. – Friability of tablets was measured according to Ph. Eur. 8, using a Pharma-
test PTF 10ER apparatus (Pharmatest, Germany), operated at 25 rpm for 4 minutes. Friabil-
ity was calculated using the total weight of tablets before and after the test.
Resistance to crushing. – Resistance to crushing was determined with a Pharmatest 
WHT 3ME apparatus (Pharmatest, Germany) using 10 tablets. The average was calculated 
from individual values.
Dissolution studies. – Dissolution studies were performed on a Hanson Research SR8 
Plus dissolution tester (Hanson Research, USA) using the rotating paddle method (Appa-
ratus 2) at 100 rpm in 900 mL 0.05 mol L–1 phosphate buffer pH 6.8, maintained at 37 ± 0.5 
°C. Samples of 5 mL were withdrawn at 5, 10, 15, 30 and 45 minutes (for ENA, the last time 
point was at 30 min) employing an autosampler (Hanson Resarch Autoplus Maximizer 
and Autoplus Multifill). Samples were separately analyzed for ENA and IND contents ac-
cording to the HPLC methods described in the United States Pharmacopoeia (USP) mono-
graphs Enalapril maleate tablets and Indapamide tablets (14) using an Agilent 1200 DAD-
FL modular HPLC system (Agilent Technologies, USA).
Experimental design and statistical analysis
Experimental design and statistical analysis were performed using the Modde 10.1 
software (Umetrics, Sweden). Two separate designs were employed: one for the evaluation 
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of powder mixture characteristics and a separate one for the investigation of tablet proper-
ties. The second design was essential for testing the impact of another factor, compression 
force, on tablet quality. To observe the effect on product characteristics, variables were al-
tered in a larger region. High and low levels for the independent variables were selected 
according to literature data (15, 16) and our knowledge gained from previous experiments 
(Table I). Spray-dried lactose content was varied in order to achieve the indicated excipient 
proportions according to the selected design run.
For the evaluation of powder mixtures, the dependent variables (responses) were as 
follows: flow rate (Y1), angle of repose (Y2), moisture content (Y3), bulk density (Y4) and 
tapped density (Y5). Tablets were characterized in terms of resistance to crushing (Y1’), 
friability (Y2’) and disintegration time (Y3’).
For the purpose of screening, a linear model, fractional factorial design of resolution 
IV, was selected to evaluate powder properties (4 factors at 2 levels; 8 factorial and 3 repli-
cate points, totaling 11 runs). Tablets were evaluated according to a linear model, frac-
tional factorial design of resolution III (5 factors, 2 levels; 8 factorial and 3 replicate points, 
totaling 11 runs). To avoid systematic errors, experiments were randomized and performed 
according to the generated design.
Obtained models were evaluated using the multiple linear regression (MLR) method. 
The performance indicators monitored were R2 (goodness of fit), Q2 (goodness of predic-
tion), model validity (based on the lack of fit test, as part of the ANOVA evaluation) and 
reproducibility.
RESULTS AND DISCUSSION
In the pharmaceutical industry, approaches that might shorten drug development 
timeline are much sought-after. In order to bring clinical or generic candidates through the 
pipeline, reduction of early formulation development time and costs is crucial. One ap-
proach to accomplish this goal is to use the experimental design approach. In our study, 
the use of two fractional experimental designs was employed in order to gain maximal 
process information from minimal experimental runs. Since API costs are high, its supply 
is often limited and, in our formulation, only low dose API was utilized, design runs were 
performed with placebo mixtures, further minimalizing development costs. To verify the 




MCC proportion (%) X1 30 70
Sodium croscarmellose proportion (%) X2   1   8
Magnesium stearate proportion (%) X3        0.25   3
Blending time with lubricant (min) X4   2 10
Compression force (kN) X5   3 10
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predicted optimal formulation and its suitability as a dosage form, optimized formula-
tions with and without API were prepared and compared.
Models for powder properties
After obtaining a raw dataset of powder blend analysis (Table IIa), the obtained mod-
el was evaluated using the DoE software. The first step in analyzing the data is to evaluate 
Table II. Raw data of the experimental design























N1   8 30 1 0.25   2 35.6 34.2 1.28 0.510 0.625
N2 11 70 1 0.25 10 42.5 36.7 2.42 0.438 0.562
N3   9 30 8 0.25 10 38.1 33.8 1.36 0.541 0.662
N4   3 70 8 0.25   2 52.5 39.0 2.56 0.415 0.556
N5   2 30 1 3 10 36.8 38.9 1.20 0.500 0.625
N6   7 70 1 3   2 58.0 41.3 2.50 0.403 0.529
N7   4 30 8 3   2 40.3 38.9 1.40 0.499 0.610
N8   6 70 8 3 10 54.4 42.5 2.62 0.399 0.532
N9   5 50    4.5 1.625   6 43.1 39.0 1.82 0.442 0.575
N10   1 50    4.5 1.625   6 42.7 37.9 1.90 0.465 0.575
N11 10 50    4.5 1.625   6 48.9 38.7 1.84 0.450 0.581
Y1 – flow rate, Y2 – angle of repose, Y3 – moisture content, Y4 – bulk density, Y5 – tapped density





















N1’   3 30 1 0.25 10 10 104 0.08 13
N2’   5 70 1 0.25   2   3   40 0.15 14
N3’   6 30 8 0.25 10   3   11 1.43 16
N4   2 70 8 0.25   2 10 167 0.02 45
N5   9 30 1 3   2 10   83 0.20 34
N6   8 70 1 3 10   3   28 0.43 18
N7   7 30 8 3   2   3     7 3.32 31
N8 10 70 8 3 10 10 117 0.07 97
N9 11 50    4.5   1.625   6      6.5   69 0.08 24
N10   1 50    4.5   1.625   6      6.5   69 0.12 23
N11   4 50    4.5   1.625   6      6.5   65 0.17 28
Y1’ – resistance to crushing, Y2’ – friability, Y3’ – disintegration time
197
Z-I. Szabo et al.: Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate 
and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206.
 
the replicate plot for each response (Fig. 1a). In the replicate plot, response values are plot-
ted against experimental run numbers, replicate runs being shown on the same bar (11). 
In all cases, variations of replicated center points were much smaller than the variation in 
the entire investigation series, meaning that replicate errors did not interfere with data 
analysis.
In regression analysis, normally distributed responses give better model estimates 
and higher reliability (11). Histogram plots of responses indicated approximately normal 
distributions (results not shown) for all dependent variables, except for the flow rate, for 
Fig. 1. Replicate plot of responses: a) model for powder properties, b) model for tablet properties. 
Numbers represent individual experiments.
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which the distribution of results showed positive skewness. A simple logarithmic trans-
formation was applied to normalize the distribution for the dataset.
The Summary of Fit Plot for all responses is shown in Fig. 2a. For a model to pass this 
diagnostic test, both R2 and Q2 should have high values, while the difference between the 
two terms should not be more than 0.2–0.3, higher values indicating an inappropriately 
selected model (11).
Fig. 2. Summary of fit plot: a) model for powder properties, b) model for tablet properties.
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The linear models selected showed good quality, with R2 values greater or equal to 
0.90 and Q2 values ranging from 0.58 (Y1, flow rate) to 0.98 (Y3, moisture content). Model 
validity (third bar) shows whether the appropriate model was selected. Values greater than 
0.25 point to a valid model, while lower values indicate possible model selection problems. 
For the models selected, all values were greater than or equal to 0.37, while in the case of 
reproducibility (fourth bar), values greater than 0.79 were achieved. In general, reproduc-
ibility values lower than 0.5 indicate poor experimental control and large pure error (11).
Another important diagnostic test of model validity is the analysis of variance (ANO-
VA) and its lack of fit test. Table IIIa represents the extracted summaries of the tests for all 
responses. Two F-tests were performed during the analysis; the first assessed the signifi-
cance of the response model, while the second test compared model error and replicate 
error (11). For all responses, significant regression models were obtained (p < 0.05) and no 
lack of fit was detected (p > 0.05).
Models for tablet properties
Tablets were prepared according to the selected design and evaluated for the specified 
responses. Raw data of the results is presented in Table IIb. The fitted model passed the 
replicative plot analysis for all responses, pointing to low replicate errors (Fig. 1b).
Normal distribution plot of the data was obtained for resistance to crushing, but not 
for friability and disintegration time. In both cases, the histograms showed strong positive 
Table III. Extracted summaries of ANOVA evaluation for the responses
Model for powder characteristics
Response
Regression Lack of fit
F-value p-value F-value p-value
Y1   12.833    0.004   0.737 0.645
Y2   29.810 < 0.001   2.029 0.356
Y3 252.186 < 0.001   2.067 0.352
Y4   33.259 < 0.001   1.250 0.490
Y5   42.995 < 0.001 11.639 0.081
Y1 – flow rate (s), Y2 – angle of repose (°), Y3 – moisture content (%), Y4 – bulk density (g mL–1), Y5 – tapped density 
(g mL–1)
Model for tablet characteristics
Response
Regression Lack of fit
F-value p-value F-value p-value
Y1’ 101.612 < 0.001 8.176 0.109
Y2’   16.055    0.004 1.801 0.376
Y3’   27.620    0.001 3.029 0.258
Y1’ – resistance to crushing (N), Y2’ – friability (%), Y3’ – disintegration time (s)
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skewness, indicating that the frequency of lower values was much higher. In order to 
achieve approximately normal distribution plots, logarithmic transformations were used 
for both responses. These transformations resulted in an increase of Q2 from 0.13 to 0.86 
(Y2’ friability) and 0.66 from –0.40 (Y3’ disintegration time). For Y1’ (resistance to crush-
ing), the value obtained for experiment N4’ (167 N) was detected as an outlier and was 
eliminated, resulting in better model performances.
The Summary of Fit plot (Fig. 2b) indicated that the linear model had acceptable qual-
ity, with R2 values between 0.94 and 0.99 and Q2 values between 0.66 and 0.94; the highest 
difference between the two indicators was 0.31 (Y3’ disintegration time). The models were 
characterized by high reproducibility, while model validities were within acceptable lim-
its, the findings being supported by the good performances during ANOVA analysis (Ta-
ble IIIb).
Evaluation of variables affecting powder mixture properties
Flowability of powder mixtures has a great influence on tableting characteristics, 
since it confers a uniform feed of the powder into the tablet press, ensuring mass and 
content uniformity (17, 18). To study the influence of the variables on flow behavior, coef-
ficient plots were constructed using the DoE software (Fig. 3a). Among the studied vari-
ables, MCC proportion (X1) proved to have the greatest impact on powder characteristics, 
significantly influencing all responses. Cellulose type was shown to have a great influence 
on the resulting tablet properties (19–21). Vivapur 102 is a fine-grade microcrystalline cel-
lulose and due to its anisometric particles and low density, its mass flow is lower compared 
to other diluents (22). Accordingly, in our case, powders with increased cellulose content 
also showed poorer flowability compared to formulations with higher lactose content. 
Flowlac 100, characterized by its spherical shape of spray-dried aggregates, larger particle 
size and thus low cohesion (23) confers better flow characteristics to powder blends.
Apart from the MCC content, the flow rate also decreased with increased lubricant 
percentage (X3); however, the negative effect on powder flow was more pronounced when 
measuring the angle of repose. This behavior came as a surprise, since increased magne-
sium stearate content of powders was linked with improved flow characteristics (24–26) by 
reducing adhesion and capillary forces (27, 28). Lubrication, however, is not only depen-
dent on the lubricant content, but also on the blending time and mixing intensity. In par-
ticular, when mixed for longer periods, several lubricants formed films on the surface of 
larger particles, which in turn improved flowability (29–31). Examining the anomaly in our 
situation, it is presumed that the interval of mixing time with lubricant could have led to 
inadequate blending. This assumption is based on the observation that mixing time had a 
slight positive effect on both the flow rate and angle of repose (i.e., small decrease in both 
parameters with prolonged mixing time). Analyzing the moisture content of the powder 
blends, MCC proportion showed a strong positive correlation, as expected, while other 
variables had only a small or no effect at all. Higher moisture content of powder blends 
with increased MCC proportion is thoroughly discussed in literature, in fact, hygroscopic 
behavior of MCC is one of its main limitations when used as a diluent (32–35).
Densities of the prepared powder mixtures decreased with increased MCC content, 
mostly due to an increase in cohesive forces between MCC particles when compared to 
spray dried lactose.
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Evaluation of variables affecting tablet properties
Tablets were evaluated in terms of resistance to crushing (Y1’), friability (Y2’) and 
disintegration time (Y3’). The coefficient plot for the selected responses (Fig. 3b) revealed 
the significance of compression force (X5) upon tablet characteristics, which, in our case, 
proved to be the most important factor to control. As expected, there was a strong positive 
Fig. 3. Coefficient plots for responses: a) model for powder properties, b) model for tablet properties. 
X1 – MCC proportion (%), X2 – sodium croscarmellose proportion (%), X3 – MgSt proportion (%), X4 
– bending time with lubricant (min), X5 – compression force (kN).
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linear correlation between compression force and resistance to crushing (correlation coef-
ficient, R = 0.94). Except for experiment N4’ (resistance to crushing 167 N), values obtained 
for this parameter were between 7 and 117 N, with center points situated around the value 
of 70 N. Although in a smaller proportion than compression force, MCC content (X1) also 
proved to be significant for achieving high tablet hardness. Increasing the MCC ratio re-
sulted in an increase in resistance to crushing, cellulose exhibiting better compactibility 
and thus conferring higher tablet hardness (36). Increasing the MgSt content (X3) led to a 
small decrease in resistance to crushing values, while other factors did not seem to con-
tribute significantly.
In the case of uncoated tablets, friability not greater than 1 % is considered acceptable 
under current regulations. All formulations, except for N3’ and N7’, showed lower friabil-
ity values than the maximum allowed ones. It is noteworthy that the two mentioned for-
mulations exhibited also the lowest resistance to crushing (11 N and 7 N, respectively). 
Upon examination, the correlation matrix revealed a negative correlation between resis-
tance to crushing and friability, higher tablet hardness being related to lower friability 
values (R = –0.86). This finding was also supported by the lower friability values obtained 
when employing higher compression forces. Increase in lubricant content (X3) led to an 
increase in friability; however, the impact of the variable was lower than that of the other 
two. Sodium croscarmellose content (X2) and lubrication time (X4) seemed to have no 
significant effect on either of the two responses (resistance to crushing and friability).
When formulating immediate release tablets, rapid disintegration is considered in 
order to rapidly release the active substance from the formulation and make it readily 
available. For uncoated tablets, unless stated otherwise, current pharmacopoeial regula-
tions stipulate a maximum disintegration time of 15 minutes. As the raw dataset demon-
strates (Table IIb), all formulations disintegrated in less than 2 minutes, with the highest 
values obtained for N8’ (97 s).
Increasing the compression force reduces liquid penetration into tablets, which in 
turn increases disintegration time (37), the behavior that was observed also in our case. 
Disintegration time also increased with lubricant proportion, probably due to the hydro-
phobic film forming capacity of magnesium stearate (38) and it also increased with the 
MCC content.
Croscarmellose sodium has a high swelling capacity even at low concentrations, dis-
integrating tablets rapidly (37, 39), which in theory should have a positive effect on disin-
tegration time (i.e., decrease with increased concentration); however, in our particular case, 
it increased disintegration time. A possible explanation might be that sodium croscarmel-
lose reached its peak efficiency at low concentrations and higher ratios of the disintegrant 
with fibrous structure led to a slight increase in disintegration time due to cohesive forces. 
Also, the recorded resistances to crushing values were on the lower side, facilitating water 
penetration into tablets and allowing even low concentrations of the disintegrant to swell 
rapidly.
Formulation optimization
After completion of the screening phase, the formulation was optimized using the 
Optimizer feature of the DoE software, applying the following criteria: target value for 
resistance to crushing 80 N (min. 60 N, max. 100 N), friability minimized, with a target 
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value of 0.2 % (max. 1 %), disintegration time minimized, with a target value of 60 s (max. 
90 s).
To test the impact of the small amount of active pharmaceutical ingredients (APIs) on 
powder and tablet characteristics, the optimized formulation was prepared both with and 
without the APIs. Table IV shows the closeness of the predicted and actually obtained re-
sults for both formulations. As can be seen, differences were found only in the case of 
friability, which was still much below the pharmacopoeial limit of 1 %. Similar results 
were obtained for powder characteristics, where differences were obtained only when 
measuring the angle of repose of the powder blends (39.2 and 36.1 ° for the formulation 
with and without APIs, respectively).
In order to obtain a pharmaceutical formulation that could be used in practice, the 
tablets were coated and in vitro dissolution studies were performed for both coated and 
uncoated tablets. The coating was applied not only for aesthetic, but also for stability con-
siderations. However, since an immediate release of APIs was targeted, the coating should 
not prolong dissolution. Both formulations demonstrated very similar release profiles, in-
dicating that the application of a film layer did not change the release rate significantly 
(Fig. 4). Moreover, dissolution of both APIs corresponded with the USP stipulations (NLT 
80 % dissolved in 30 minutes for ENA and NLT 75 % dissolved in 45 minutes for IND), 
making the present formulation an interesting and cheaper alternative to other combina-
tion therapies present on the market. However, further studies need to be performed both 
in preclinical and clinical phases in order to test the stability, efficacy and suitability of this 
combination.
Table IV. Predicted and practically obtained response values for the optimized formulaa
Predicted values
Y1’ (N) Y2’ (%) Y3’ (s)
80 0.18 23
Results obtained Y1 (s) Y2 (°) Y3 (%) Y4 (g mL–1) Y5 (g mL–1) Y1’ (N) Y2’ (%) Y3’ (s)
Without APIs 34.6 36.1 1.4 0.497 0.625 76 0.11 19
With APIs 34 39.2   1.48 0.491 0.625 73 0.26 18
a Optimized formula: MCC proportion (X1) 30.8 %; sodium croscarmellose proportion (X2) 4.64 %; MgSt proportion 
(X3) 0.99 %; compression force (X4) 8.5 kN; blending time with lubricant (X5) 6 min.
Fig. 4. Comparative dissolution profiles of both coated (n) and uncoated (l) formulations (n = 6) for: 
a) ENA and b) IND. Error bars represent standard deviation values.
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CONCLUSIONS
The combination of two widely used and highly efficient antihypertensive agents, 
ENA and IND, was used in a pharmaceutical formulation as a possible cheaper alternative 
to currently used antihypertensive combinations. Design and evaluation of the formula-
tion were performed with the aid of DoE software in order to observe the effects of differ-
ent formulation and process related variables on the selected responses. To evaluate both 
powder and tablet properties, two separate experimental designs were constructed using 
the software. Since the amount of APIs in the formulations was low, it was hypothesized 
that both powder and tablet properties would be determined only by the characteristics of 
excipients. To test this assumption, both experimental designs were applied with placebo 
composition (without API). Analyzing the results of experimental runs, it was concluded 
that MCC and MgSt contents were the most important factors affecting powder character-
istics. In terms of tablet characteristics, compression force proved to be the most important 
factor to control, followed by MCC and lubricant contents.
Based on the available data, the formulation was optimized using the DoE software. 
Optimized formulations were prepared both with and without APIs. Obtained results 
were in good accord with the predicted values and no differences were found between the 
formulations with and without the APIs for the majority of responses.
In the final phase, tablets were coated for both aesthetical and stability reasons. Dis-
solution studies were performed and both coated and uncoated tablets met the pharmaco-
poeial requirements for both APIs, indicating that the coating did not interfere with the 
immediate release of active substances. The developed formulation could be a promising 
cheaper alternative to current combination treatments for hypertension. Moreover, the 
combined approach of using placebo mixtures and fractional factorial designs proved to 
be highly efficient, leading cost-effectively to optimal composition in a time saving man-
ner.
Acknowledgement. – This paper was published under the frame of the European Social Fund, 
Human Resources Development Operational Programme 2007–2013, project no. POSDRU/159/1.5/S/ 
136893.
REFERENCES
  1.  B. Gil-Extremera and P. Cía-Gómez, Hypertension in the elderly, Int. J. Hypertens. 2012 (2012) 
859176; DOI: 10.1155/2012/859176.
  2.  P. W. de Leeuw, Combination perindopril/indapamide for the treatment of hypertension: a re-
view, Expert Opin. Pharmacother. 12 (2011) 1827–1833; DOI: 10.1517/14656566.2011.585638.
  3.  S.-S. Huang, T.-C. Wu, S.-J. Lin and J.-W. Chen, Combination of an ACE inhibitor and indapamide 
improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma 
adiponectin in patients with essential hypertension, Circ. J. 73 (2009) 2282–2287.
  4.  S. Kalra, B. Kalra and N. Agrawal, Combination therapy in hypertension: An update, Diabetol. 
Metab. Syndr. 2 (2010) 44; DOI: 10.1186/1758-5996-2-44.
  5.  C. L. Brown, C. I. Backhouse, J. C. Grippat and J. P. Santoni, The effect of perindopril and hydro-
chlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system 
in hypertensive subjects, Eur. J. Clin. Pharmacol. 39 (1990) 327–332.
205
Z-I. Szabo et al.: Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate 
and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206.
 
  6.  S. G. Mallat, H. S. Itani and B. Y. Tanios, Current perspectives on combination therapy in the 
management of hypertension, Integr. Blood Press. Control 6 (2013) 69–78; DOI: 10.2147/IBPC.S33985.
  7.  L. Cavalieri and G. Cremonesi, Delapril plus indapamide: a review of the combination in the treat-
ment of hypertension, Clin. Drug Investig. 27 (2007) 367–380.
  8.  I. N. Belenkov, F. T. Ageev, I. A. Orolova, O. I. Abrosimova, E. G. Volkova, L. I. Gapon, L. I. 
Katel’nitskaia, A. O. Kondari, I. F. Patrusheva, I. V Fomin and R. A. Khokhlov, Clinical and vascu-
lar effects of ACE inhibitor enalapril in combination with thiaside-like diuretic indapamide in 
hypertensive outpatients. Results of the multicenter trial POEMA, Ter. Arkh. 79 (2007) 33–38.
  9.  S. C. Sweetman, Martindale: The Complete Drug Reference, 37th ed., Pharmaceutical Press, London 
2011.
10.  D. C. Montgomerey, Design and Analysis of Experiments, 7th ed., John Wiley & Sons, Hoboken, New 
York 2009.
11.  L. Erikkson, E. Johansson, N. Kettaneh-Wold, C. Wilkström and S. Wold, Design of Experiments: 
Principles and Applications (Third revised and enlarged edition), MKS Umetrics AB, Umea 2008.
12.  A. Curić, R. Reul, J. Möschwitzer and G. Fricker, Formulation optimization of itraconazole loaded 
PEGylated liposomes for parenteral administration by using design of experiments, Int. J. Pharm. 
448 (2013) 189–197; DOI: 10.1016/j.ijpharm.2013.03.029.
13.  European Pharmacopoeia, 7th ed., Council of Europe, Strasburg 2010.
14.  United States Pharmacopoeia, 35th ed., United States Pharmacopeial Convention, Rockville MD 2011.
15.  I. Popovici and D. Lupuleasa, Tehnologie Farmaceutica, Vol. 3, Editura Polirom, București 2009.
16.  R. C. Rowe, P. J. Sheskey and M. E. Quinn (editors), Handbook of Pharmaceutical Excipients, 6th ed., 
Pharmaceutical Press, London 2009.
17.  L. X. Liu, I. Marziano, A. C. Bentham, J. D. Litster, E. T. White and T. Howes, Effect of particle 
properties on the flowability of ibuprofen powders, Int. J. Pharm. 362 (2008) 109–117; DOI: 10.1016/j.
ijpharm.2008.06.023.
18.  M. Leturia, M. Benali, S. Lagarde, I. Ronga and K. Saleh, Characterization of flow properties of 
cohesive powders: A comparative study of traditional and new testing methods, Powder Technol. 
253 (2014) 406–423; DOI: 10.1016/j.powtec.2013.11.045.
19.  C. T.-Y. Pourcelot, Preformulation of five commercial celluloses in drug development: Rheological 
and mechanical behaviour, Drug Dev. Ind. Pharm. 19 (1993) 1947–1964; DOI: 10.3109/03639049309073901.
20.  P. Kleinebudde, M. Jumaa and F. El Saleh, Influence of the degree of polymerization on the behav-
ior of cellulose during homogenization and extrusion/spheronization, AAPS PharmSci 2 (2000) 
E21.
21.  T. Suzuki and H. Nakagami, Effect of crystallinity of microcrystalline cellulose on the com-
pactability and dissolution of tablets, Eur. J. Pharm. Biopharm. 47 (1999) 225–230.
22.  G. Thoorens, F. Krier, B. Leclercq, B. Carlin and B. Evrard, Microcrystalline cellulose, a direct 
compression binder in a quality by design environment-A review, Int. J. Pharm. 473 (2014) 64–72; 
DOI: 10.1016/j.ijpharm.2014.06.055.
23.  J. Muzíková and P. Sináglová, Comparison of properties of tablets and energy profile of compac-
tion of two spray-dried lactoses, Acta Pol. Pharm. 70 (2013) 129–135.
24.  F. Podczeck and Y. Mia, The influence of particle size and shape on the angle of internal friction 
and the flow factor of unlubricated and lubricated powders, Int. J. Pharm. 144 (1996) 187–194; DOI: 
10.1016/S0378-5173(96)04755-2.
25.  A. Mehrotra, M. Llusa, A. Faqih, M. Levin and F. J. Muzzio, Influence of shear intensity and total 
shear on properties of blends and tablets of lactose and cellulose lubricated with magnesium 
stearate, Int. J. Pharm. 336 (2007) 284–291; DOI: 10.1016/j.ijpharm.2006.12.013.
206
Z-I. Szabo et al.: Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate 
and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206.
 
26.  L. X. Liu, I. Marziano, A. C. Bentham, J. D. Litster, E. T. White and T. Howes, Effect of particle 
properties on the flowability of ibuprofen powders, Int. J. Pharm. 362 (2008) 109–117; DOI: 10.1016/j.
ijpharm.2008.06.023.
27.  G. Gold, R. N. Duvall, B. T. Palermo and J. G. Slater, Powder flow studies III. Factors affecting the 
flow of lactose granules, J. Pharm. Sci. 57 (1968) 667–671; DOI: 10.1002/jps.2600570429.
28.  A. M. N. Faqih, A. Mehrotra, S. V Hammond and F. J. Muzzio, Effect of moisture and magnesium 
stearate concentration on flow properties of cohesive granular materials, Int. J. Pharm. 336 (2007) 
338–345; DOI: 10.1016/j.ijpharm.2006.12.024.
29.  A. C. Shah and A. R. Mlodozeniec, Mechanism of surface lubrication: Influence of duration of 
lubricant-excipient mixing on processing characteristics of powders and properties of compressed 
tablets, J. Pharm. Sci. 66 (1977) 1377–1382; DOI: 10.1002/jps.2600661006.
30.  M. E. Johansson and M. Nicklasson, Investigation of the film formation of magnesium stearate by 
applying a flow-through dissolution technique, J. Pharm. Pharmacol. 38 (1986) 51–54; DOI: 10.1111/
j.2042-7158.1986.tb04466.x.
31.  C. F. Lerk, G. K. Bolhuis and S. S. Smedema, Interaction of lubricants and colloidal silica during 
mixing with excipients. I. Its effect on tabletting, Pharm. Acta Helv. 52 (1977) 33–39.
32.  V. Nicolas, O. Chambin, C. Andrès, M. H. Rochat-Gonthier and Y. Pourcelot, Preformulation: effect 
of moisture content on microcrystalline cellulose (Avicel PH-302) and its consequences on pack-
ing performances, Drug Dev. Ind. Pharm. 25 (1999) 1137–1142; DOI: 10.1081/DDC-100102280.
33.  G. E. Amidon and M. E. Houghton, The effect of moisture on the mechanical and powder flow 
properties of microcrystalline cellulose, Pharm. Res. 12 (1995) 923–929; DOI: 10.1023/A:1016233725612.
34.  A. Mihranyan, A. P. Llagostera, R. Karmhag, M. Strømme and R. Ek, Moisture sorption by cellu-
lose powders of varying crystallinity, Int. J. Pharm. 269 (2004) 433–442; DOI: 10.1016/j.ijpharm.2003. 
09.030.
35.  C. C. Sun, Mechanism of moisture induced variations in true density and compaction properties 
of microcrystalline cellulose, Int. J. Pharm. 346 (2008) 93–101; DOI: 10.1016/j.ijpharm.2007.06.017.
36.  I. Jivraj, L. Martini and C. Thomson, An overview of the different excipients useful for the direct 
compression of tablets, Pharm. Sci. Technolo. Today 3 (2000) 58–63; DOI: 10.1016/S1461-5347(99)00237-0.
37.  C. Ferrero, N. Muñoz, M. V. Velasco, A. Muñoz-Ruiz and R. Jiménez-Castellanos, Disintegrating 
efficiency of croscarmellose sodium in a direct compression formulation, Int. J. Pharm. 147 (1997) 
11–21; DOI: 10.1016/S0378-5173(96)04784-9.
38.  N. O. Lindberg, Evaluation of some tablet lubricants, Acta Pharm. Suec. 9 (1972) 207–214.
39.  A. F. Marais, M. Song and M. M. D. V. Φ, Effect of compression force, humidity and disintegrant 
concentration on the disintegration and dissolution of directly compressed furosemide tablets 
using croscarmellose sodium as disintegrant, Trop. J. Pharm. Res. 2 (2003) 125–135.
